UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	, FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/728,873	12/08/2003	Paul McGlynn	00324/US1	1167
24330 Martin A. Hay	7590 03/22/200	1	EXAM	INER
13 Queen Victoria Street			PUTTLITZ, KARL J	
Macclesfield Cl UNITED KINC	heshire UK, SK11 6LP 3DOM		ART UNIT	PAPER NUMBER
•			1621	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS		03/22/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)			
Office Action Summary		10/728,873	MCGLYNN ET AL.			
		Examiner	Art Unit			
		Karl J. Puttlitz	1621			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE is not of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period ver to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUM 36(a). In no event, however, may will apply and will expire SIX (6), cause the application to become	UNICATION.  By a reply be timely filed  MONTHS from the mailing date of this communication.  BY ABANDONED (35 U.S.C. § 133).			
Status						
1)⊠	Responsive to communication(s) filed on <u>04 Ja</u>	anuary 2007.				
· · · —		action is non-final.	•			
<i>,</i> —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
٠,۵	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
· _	4)⊠ Claim(s) <u>1-29</u> is/are pending in the application.					
-	4a) Of the above claim(s) is/are withdrawn from consideration.					
	(i)					
•	5)⊠ Claim(s) <u>75-25,24 unit 27-25</u> is/are allowed. 5)⊠ Claim(s) <u>21-23</u> is/are rejected.					
	Claim(s) <u>25 and 26</u> is/are objected to.		•			
·	·					
	,	,				
Applicati	on Papers					
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the	drawing(s) be held in abe	eyance. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	ınder 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
			KARL PUTTLITZ PATENT EXAMINER			
2) Notic 3) Inform	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	Paper 5) 🔲 Notice	ew Summary (PTO-413) No(s)/Mail Date of Informal Patent Application			

## **DETAILED ACTION**

The rejection under section 112, first paragraph is withdrawn since the specification teaches preparation of levalbuterol L-tartrate in crystalline form.

The rejection under section 103 is withdrawn since the references does not particularly suggest the L-tartrate salts of levalbuterol. In this regard, common salts of pharmaceutical products would have been within the motivation and skill of those of ordinary skill, and thus prima facie obvious. In this connection, the examiner mentions the art of record and Berge et al., Journal of Pharmaceuticals 66(1) (1977), which demonstrates the common salts: hydrochloride, sulfate and tartrate (see table I on page 2). However, the Declaration under Rule 1.132 shows that tartrate salts, as opposed to the sulfates, and hydrochloride salts (shown in the specification), could not be formed into micronized pellets, suitable for administration with a metered does inhaler. However, the L-tartrate salts of levalbuterol could unexpectedly be micronized, and be suitable administered via a metered-does inhaler. Therefore, the showing under Rule 1.132 shows unexpected results of the L-tartrate salts, and thus, overcomes the prima facie case.

An updated search of the prior art failed to uncover a reference that teaches levalbuterol L-tartrate. The search also failed to uncover a reference that would have motivated those of ordinary skill to modify a know compound to provide the levalbuterol L-tartrate of the instant claims. In this regard, CN 1382685 teaches the tartrate salt of levalbuterol, see attached CAS online citation [retrieved March 16, 2007] from STN,

Application/Control Number: 10/728,873

Art Unit: 1621

Columbus, OH, USA. However, the Declaration under Rule 1.131 dated 7/3/2006 shows a reduction of practice in March 2002, which antedates this reference.

Claims 15, 16 and 18-29 are rejoined under MPEP 821.04(a). In this regard, the following objections and rejections are now entered:

## Claim Objections

Claims 26 and 26 objected to because of the following informalities: the term "whenever" should be removed. Appropriate correction is required.

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 21-23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 21 recites preparation of levalbuterol L-tartrate by hydrogenation of R-benzylalbuterol. However, it is unclear how the L-tartrate salt is prepared in this manner. Moreover, claim 21 depends on claim 18, and in this manner it is unclear how hydrogenation integrates with the mixing of levalbuterol with tartaric acid.

Application/Control Number: 10/728,873 Page 4

Art Unit: 1621

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karl J. Puttlitz whose telephone number is (571) 272-0645. The examiner can normally be reached on Monday to Friday from 9 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page, can be reached at telephone number (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KARL PUTTLITZ PATENT EXAMINER

3/16/07